Functional MR in Ischemic Cardiomyopathy

功能性磁共振在缺血性心肌病中的应用

• 批准号: 6930425
• 负责人: Paul A Grayburn
• 金额: $ 33.82万
• 依托单位: BAYLOR RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6930425
• 关键词: cardiovascular imaging /visualization; clinical research; clinical trials; coronary bypass; disease /disorder etiology; echocardiography; electrocardiography; heart revascularization; human subject; human therapy evaluation; medical complication; mitral valve insufficiency; myocardial infarction; myocardial ischemia /hypoxia; pathologic process; patient oriented research; prognosis

DESCRIPTION (provided by applicant): Functional mitral regurgitation (MR) is a common complication of ischemic heart disease. Two large clinical trials confirmed an adverse effect of functional MR on survival after a heart attack. However, studies in heart failure are small and mainly limited to patients with nonischemic cardiomyopathy. Recent animal studies have challenged the traditional concept that functional MR is a consequence of mitral annular dilation, instead suggesting that functional MR is due to leaflet tethering by outward expansion of the left ventricular wall (i.e. LV remodeling). This has critical implications regarding the correct surgical approach to correcting functional MR. TO date, no large prospective studies have examined the mechanism(s) of functional MR in ischemic cardiomyopathy, nor has the interaction between mechanism and prognosis been explored. This is a crucial knowledge gap because 1) 70% of heart failure cases are caused by ischemic heart disease, and 2) functional MR occurs in around 60% of patients with ischemic cardiomyopathy. This proposal aims to fill these gaps by defining the mechanism(s) of functional MR by transesophageal echocardiography in a large clinical trial of patients with ischemic cardiomyopathy. The following specific aims will be addressed: Aim 1: To define the mechanism(s) of functional MR in ischemic cardiomyopathyAim 2: To define the effect of therapy on mechanism and severity of functional MRAim 3: To evaluate the effect of functional MR on prognosis is ischemic cardiomyopathyAim 4: To evaluate the effect of myocardial viability on functional MR and its response to treatment We propose to accomplish these aims as a ancillary study to the Surgical Treatment of Ischemic Heart Failure (STICH) Trial. The STICH Trial will compare surgical revascularization versus medical therapy for treatment of heart failure in 2800 patients with ischemic cardiomyopathy, and therefore affords a unique opportunity to investigate the mechanism(s) of functional MR. Despite its known clinical utility of assessing the mechanism and severity of MR, TEE is not currently included in STICH.

DESCRIPTION (provided by applicant): Functional mitral regurgitation (MR) is a common complication of ischemic heart disease. Two large clinical trials confirmed an adverse effect of functional MR on survival after a heart attack. However, studies in heart failure are small and mainly limited to patients with nonischemic cardiomyopathy. Recent animal studies have challenged the traditional concept that functional MR is a consequence of mitral annular dilation, instead suggesting that functional MR is due to leaflet tethering by outward expansion of the left ventricular wall (i.e. LV remodeling). This has critical implications regarding the correct surgical approach to correcting functional MR. TO date, no large prospective studies have examined the mechanism(s) of functional MR in ischemic cardiomyopathy, nor has the interaction between mechanism and prognosis been explored. This is a crucial knowledge gap because 1) 70% of heart failure cases are caused by ischemic heart disease, and 2) functional MR occurs in around 60% of patients with ischemic cardiomyopathy. This proposal aims to fill these gaps by defining the mechanism(s) of functional MR by transesophageal echocardiography in a large clinical trial of patients with ischemic cardiomyopathy. The following specific aims will be addressed: Aim 1: To define the mechanism(s) of functional MR in ischemic cardiomyopathyAim 2: To define the effect of therapy on mechanism and severity of functional MRAim 3: To evaluate the effect of functional MR on prognosis is ischemic cardiomyopathyAim 4: To evaluate the effect of myocardial viability on functional MR and its response to treatment We propose to accomplish these aims as a ancillary study to the Surgical Treatment of Ischemic Heart Failure (STICH) Trial. The STICH Trial will compare surgical revascularization versus medical therapy for treatment of heart failure in 2800 patients with ischemic cardiomyopathy, and therefore affords a unique opportunity to investigate the mechanism(s) of functional MR. Despite its known clinical utility of assessing the mechanism and severity of MR, TEE is not currently included in STICH.